{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:14:00Z","timestamp":1789823640881,"version":"4.0.1"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T00:00:00Z","timestamp":1324512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> The treatment of Kawasaki disease patients who fail to respond to initial i.v. immunoglobulin (IVIG) therapy is controversial. The aim of the present study was to investigate the long\u2010term efficacy of plasma exchange (PE) treatment for refractory Kawasaki disease.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> A total of 125 Kawasaki disease patients refractory to IVIG were treated with PE. Coronary artery lesions (CAL) before PE, in the acute period, and during the late period were examined retrospectively.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Residual sequelae requiring medical treatment occurred in six cases in the late period. The outcomes of treatment tended to be better when PE was begun in the early stage. Sequelae remained in 2.8% of patients in whom PE was initiated prior to day 9 after onset, and were present in 15% of patients in whom PE was started on or after day 10. The 105 patients whose coronary arteries were normal before PE had no sequelae (residual sequelae: 0%). Dilatation was present before PE in 14 patients, but remained in only two patients in the late period (residual sequelae, 14.3%). In four of the six patients in whom aneurysms had already formed before PE, the lesions had advanced into giant aneurysms, but in the other two patients they returned to the normal range (residual sequelae, 66.6%).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> The outcomes of PE for Kawasaki disease refractory to IVIG are favorable, and the effectiveness of this treatment is excellent, particularly if it is initiated before CAL arise.<\/jats:p>","DOI":"10.1111\/j.1442-200x.2011.03487.x","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T13:16:36Z","timestamp":1318857396000},"page":"99-103","source":"Crossref","is-referenced-by-count":69,"title":["Long\u2010term efficacy of plasma exchange treatment for refractory Kawasaki disease"],"prefix":"10.1111","volume":"54","author":[{"given":"Tatsunori","family":"Hokosaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumpei","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2182"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199812000-00009"},{"key":"e_1_2_6_4_2","first-page":"79","article-title":"Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins","volume":"44","author":"Villain E","year":"1987","journal-title":"Arch. Fr. Pediatr."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91916-3"},{"key":"e_1_2_6_6_2","unstructured":"Research Committee on Kawasaki Disease Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Japanese Ministry of Health and Welfare Tokyo Japan 1984."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.107890"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-003-0264-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1267-y"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70447-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.062299"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.258"},{"key":"e_1_2_6_13_2","first-page":"803","article-title":"Corticosteroid treatment of refractory Kawasaki disease","volume":"33","author":"Lang BA","year":"2006","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1386-5"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.126144"},{"key":"e_1_2_6_16_2","first-page":"304","article-title":"Frequency of coronary artery lesions in cases treated with steroids in the acute period.","volume":"24","author":"Ogino K","year":"2008","journal-title":"Pediatr. Cardiol. Cardiac. Surg."},{"key":"e_1_2_6_17_2","first-page":"304","article-title":"Analysis of coronary artery lesions in cases treated with steroids in the acute period","volume":"24","author":"Suzuki H","year":"2008","journal-title":"Pediatr. Cardiol. Cardiac. Surg."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(90)90166-N"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91910-7"},{"key":"e_1_2_6_20_2","first-page":"651","article-title":"Elevated circulating tumor necrosis factor\u2010alpha in patients with Kawasaki disease","volume":"113","author":"Maury CP","year":"1989","journal-title":"J. Lab. Clin. Med."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81361-7"},{"key":"e_1_2_6_22_2","first-page":"808","article-title":"Infliximab as a novel therapy for refractory Kawasaki disease","volume":"31","author":"Weiss JE","year":"2004","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.12.022"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.06.011"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20143"}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-200X.2011.03487.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-200X.2011.03487.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T16:38:26Z","timestamp":1697301506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-200X.2011.03487.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,22]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1442-200X.2011.03487.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-200x.2011.03487.x","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,22]]}}}